The Impact of Reducing Stavudine dose versus switching to tenofovir on plasma lipids,body composition and mitochondrial function in HIV-infected patients

Abstract

Background

Stavudine (d4T)-containing regimens are associated with a potential for lipoatrophy and dyslipidaemia. We assessed the safety and efficacy of reducing the dose of stavudine compared with switching to tenofovir or maintaining the standard dose of d4T.

Methods

Clinically stable HIV-infected patients receiving antiretroviral therapy containing stavudine 40 mg twice daily with a plasma HIV RNA <200 copies/ml for at least 6 months were randomized to maintain stavudine 40 mg twice daily (d4T40 arm), to reduce to 30 mg twice daily (d4T30 arm), or to switch from d4T to tenofovir (TDF arm).

Results

Fifty-eight (93% male) patients were included: 22 in the d4T40 arm, 19 in the d4T30 arm and 17 in TDF arm. At baseline, median time on d4T was 6 years (interquartile range [IQR] 2.6–7.1), median age 43 years (IQR 36–51) and median CD4⁺ T-cell count was 587/mm³ (IQR 329–892). At week 24, median limb fat changes (g) were as follows: d4T40=-182 (95% CI: -469—5); d4T30=527 (95% CI: -343–694); and TDF=402 (95% CI: 130–835; d4T40 versus TDF, P=0.0003). Significant differences between median values of laboratory parameters were detected: triglycerides (mg/dl): d4T40=19; d4T30=-23 and TDF=-79 (d4T40 versus TDF, P=0.03); and total cholesterol (mg/dl): d4t40=22, d4T30=-4, and TDF=-28 (d4T40 versus TDF, P=0.04). No significant difference was observed in mitochondrial function assessed in peripheral blood mononuclear cells.

Conclusions

Although both strategies were associated with a trend toward a decrease in plasma lipids and an increase in body fat, the only significant changes were observed among those who switched to tenofovir.

References

Nolan

, Hammond

, Martin

Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy.

AIDS 2003; 17: 1329–1338.

Dube

, Parker

R.A.

, Tebas

Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.

AIDS 2005; 19: 1807–18.

Gallant

, Staszewski

, Pozniak

A.L.

Long-term efficacy and safety of tenofovir disoproxil fumarate (TDF): a 144-week comparison versus stavudine (d4T) in antiretroviral-naive patients.

JAMA 2004; 292: 191–201.

Walmsley

, Horban

, Jain

Fosamprenavir/ritonavir and nelfinavir have comparable effects on body fat distribution in antiretroviral-naive patients: 48-week results from the SOLO. International Workshop on Adverse Drug Reactions and Lipodystrophy, Washington DC, USA, 25–28 October 2004. Poster L-787.

Shlay

J.C.

, Visnegarwala

, Bartsch

Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine.

J Acquir Immune Defic Syndr 2005; 38: 147–155.

Saag

M.S.

, Cahn

, Raffi

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naïve patients: a randomized trial.

JAMA 2004; 292: 180–189.

Domingo

, Labarga

, Palacios

Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results.

AIDS 2004; 18: 1475–1478.

Moyle

, Sabin

, Cartledge

A randomized comparative study of tenofovir DF or abacavir as replacement for thymidine analogue in persons with lipoatrophy.

AIDS 2006; 20: 2043–2050.

Carr

, Workman

, Smith

D.E.

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.

JAMA 2002; 288: 207–215.

10.

Martin

, Smith

D.E.

, Carr

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.

AIDS 2004; 18: 1029–1036.

11.

Sanchez-Conde

, Mendoza

, Jimenez-Nacher

Reductions in Stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity.

HIV Clin Trials 2005; 6: 197–202.

12.

Delpierre

, Cuzin

, Alvarez

Lowering stavudine dosages does not compromise anti-viral efficacy in HIV-infected patients. European AIDS Conference, Warsaw, Poland, 25–29 October 2003. Abstract 262.

13.

Hanvanich

, Prasanthai

, Riengschan

Reduction of d4T dosage improves lipoatrophy without virologic failure.

Antivir Ther 2003; 8: S392.

14.

Wolf

, Koegl

, Hoffman

Low dose stavudine: less side effects but as effective as standard dose. Program and abstracts of the 15th International AIDS Conference, Bangkok, Thailand, 11–16 July 2004. Abstract WePeB5861.

15.

Siangphoe

, Srikaew

, Waiwaravuth

Efficacy and safety of half dose compared to full dose stavudine (d4T) and zidovudine (AZT) in combination with didanosine (ddI) in Thai HIV-infected patients: 96 week results of ACTT002/ARV065 study. Program and abstracts of the 15th International AIDS Conference, Bangkok, Thailand, 11–16 July 2004. Abstract WePeB5952.

16.

Saint-Marc

, Touraine

J.L.

The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy.

AIDS 1999; 13: 2188–2189.

17.

Carr

, Samaras

, Thorisdotirr

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.

Lancet 1999; 353: 2093–2099.

18.

Carr

for Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case control study.

Lancet 2003; 361: 726–735.

19.

Kanis

J.A.

, Delmas

, Buckhardt

Guidelines for diagnosis and management of osteoporosis. The European Fundation for Osteoporosis and Bone Disease.

Osteoporos Int 1997; 7: 390–406.

20.

Bradford

A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of protein-dye binding.

Anal Biochem 1976; 72: 248–254.

21.

Cardellach

, Alonso

J.R.

, Lopez

, Casademont

, Miro

Effect of smoking cessation on mitochondrial respiratory chain function.

J Clin Toxicol 2003; 41: 223–228.

22.

Rustin

, Chretien

, Bourgeron

Biochemical and molecular investigations in respiratory chain deficiencies.

Clin Chim Acta 1994; 228: 35–51.

23.

Pallotti

, Lenaz

Isolation and subfractionation of mitochondria from animal cells and tissue culture lines.

Methods Cell Biol 2001; 65: 1–35.

24.

Zeviani

, Gellera

, Antozzi

Maternally inherited myopathy and cardiomyopathy: Association with a mutation in mitochondrial DNA tRNA^Leu(UUR).

Lancet 1991; 338: 143–147.

25.

Miró

, Cardellach

, Barrientos

Cytochrome c oxidase assay in minute amounts of human skeletal muscle using single wavelength spectrophotometers.

J Neurosci Methods 1998; 80: 107–111.

26.

López

, Miró

, Martínez

Mitochondrial effects of antiretroviral therapies in asymptomatic patients.

Antivir Ther 2004; 9: 47–55.

27.

EMEA. Efficacy and safety concerns regarding the co-administration of tenofovir disoproxil fumarate (TDF, Viread) and didanosine (ddI, Videx). Public Statement 3 March, 2005 [cited 13 December 2005]. Available from: http://www.emea.eu.int/pdfs/human/press/pus/6233105en.pdf.

28.

Laffeuillade

, Jolly

, Chadapaud

Evolution of lipid abnormalities in patients switched form stavudine to tenofovir-containing regiment.

J Acquir Immune Defic Syndr 2003; 33: 544–245.

29.

Gan

S.K.

, Samaras

, Thompson

C.H.

Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.

Diabetes 2002; 51: 3163–3169.

30.

Torriani

, Thomas

B.J.

, Barlow

R.B.

Increased intramyocellular lipid accumulation in HIV-infected women with fat redistribution.

J Appl Physiol 2006; 100: 609–614.

31.

Martin

, Vinas

, Mampel

Effects of cold environment on mitochondrial genome expression in the rat: evidence for a tissue-specific increase in the liver, independent of changes in mitochondrial gene abundance.

Biochem J 1993; 296: 231–234.

32.

Enriquez

J.A.

, Fernandez-Silva

, Montoya

Autonomous regulation in mammalian mitochondrial DNA transcription.

Biol Chem 1999; 380: 737–747.

33.

Galluzzi

, Pinti

, Troiano

Changes in mitochondrial RNA production in cells treated with nucleoside analogues.

Antivir Ther 2005; 10: 191–195.

34.

Mallon

P.W.

, Unemori

, Sedwell

In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA.

J Infect Dis 2005; 191: 1686–1696.

35.

Hoy

, Gahan

, Carr

Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir.

J Infect Dis 2004; 190: 688–692.

36.

Cossarizza

Tests for mitochondrial function and DNA: potentials and pitfalls.

Curr Opin Infect Dis 2003; 16: 5–10.

37.

Shikuma

, Hu

, Milne

Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipodystrophy.

AIDS 2001; 15: 1801–1809.

38.

Nolan

, Hammond

, Martin

Mitochondrial DNA depletion and morphological changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy.

AIDS 2003; 17: 1329–1338.

39.

Falco

, Rodriguez

, Ribera

Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature.

Clin Infect Dis 2002; 34: 838–846.

40.

Mussini

, Pinti

, Bugarini

Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study.

AIDS 2005; 19: 1627–1633.

41.

Hoy

, Gahan

, Carr

Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir.

J Infect Dis 2004; 190: 688–692.

42.

Cherry

C.L.

, Lal

, Thomson

Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patients from stavudine to abacavir or zidovudine.

J Acquir Immune Defic Syndr. 2005; 38: 263–267.

43.

Yarchoan

, Klecker

R.W.

, Weinhold

K.J.

Administration of 3’-azido-3’-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Lancet 1986; 1: 575–580.

44.

Richman

D.D.

, Grimes

J.M.

, Lagakos

S.W.

Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus.

J Acquir Immune Defic Syndr 1990; 3: 743–746.

45.

Kroon

E.D.

, Ungsedhapand

, Ruxrungtham

A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration.

AIDS 2000; 14: 1349–1356.

46.

Collier

A.C.

, Bozzette

, Coombs

R.W.

A pilot study of low-dose zidovudine in human immunodeficiency virus infection.

N England J Med 1990; 323: 1015–1021.

47.

Dudley

M.N.

, Graham

K.K.

, Kaul

Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex.

J Infect Dis 1992; 166: 480–485.

48.

Horton

, Dudley

M.N.

, Kaul

Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advance AIDS-related complex.

Antimicrob Agents Chemother 1995; 39: 2309–2315.